Migraine – Landscape & Forecast – Disease Landscape & Forecast

Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s symptoms and needs, headache pattern, comorbidities, contraindications, and treatment history. With the launch of newer migraine-specific treatment alternatives (e.g., anti-CGRP monoclonal antibodies for migraine prevention, oral CGRP receptor antagonists for both the treatment of acute migraine attacks and migraine prevention) and a range of innovative reformulations set for near-term launch in the United States, brand choice is rapidly expanding in this heavily generic market. Understanding the intersecting forces of unmet need, cost / coverage, and the headwinds posed by low-cost, early-line stand-of-care treatments will be key to the success of current and future players in migraine.

Questions Answered:

  • What events will shape the future of the acute / preventive and episodic / chronic market segments?
  • How are the anti-CGRP monoclonal antibodies (e.g., Aimovig, Emgality) and oral gepants (i.e., Nurtec ODT / Vydura, Qulipta) being integrated into the generic-dominant migraine prophylaxis market? Which brands will be the most competitive and why?
  • What is the dynamic between Ubrelvy and Nurtec ODT in the U.S. market? How are oral gepants being adopted into the triptan-dominant acute segment?
  • How will novel reformulations compete for patient share with existing options in the niche segment of patients who need non-oral alternatives?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 23 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of episodic and chronic migraine, segmented by acute and prophylactic treatment.

Emerging therapies: Phase II: 7 drugs; Phase III / preregistration: 4 drugs.

Market forecast features: Patient-based market forecast extending through 2031, segmented by brands and generics.

Product Description:

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement:

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold. Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Migraine - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Migraine key findings - November 2022
    • Key updates
      • Q4 2022
        • November 2022
      • Q3 2022
        • August 2022
      • Q2 2022
        • June 2022
        • May 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
    • Market outlook
      • Key findings
        • Market share of drug classes for the acute treatment of migraine: 2021
        • Market share of drug classes for the acute treatment of migraine: 2031
        • Market share of drug classes for the prophylactic treatment of migraine: 2021
        • Market share of drug classes for the prophylactic treatment of migraine: 2031
        • Migraine SWOT analysis
      • Market drivers and constraints
        • What factors are driving the market for migraine?
        • What factors are constraining the market for migraine?
        • Market share and treated patients for acute migraine by country: 2021 and 2031
        • Market share and treated patients for migraine prophylaxis by country: 2021 and 2031
      • Segment-specific trends
        • Sales of acute and prophylactic treatments in the episodic and chronic migraine markets: 2021 and 2031
      • Drug-class-specific trends
        • Major-market sales of key triptans in acute migraine: 2021-2031
        • Major-market patient share of key triptans in acute migraine: 2021-2031
        • U.S. sales of emerging acute treatments in migraine: 2021-2031
        • Anti-CGRP monoclonal antibodies
        • CGRP receptor antagonists
        • Major-market sales of CGRP-targeted therapies for migraine prophylaxis: 2021-2031
        • Major-market patient share of CGRP-targeted therapies for migraine prophylaxis in episodic migraine: 2021-2031
        • Major-market patient share of CGRP-targeted therapies for migraine prophylaxis in chronic migraine: 2021-2031
        • Major-market sales of other prophylactic treatments in migraine: 2021-2031
        • Major-market patient share of other prophylactic treatments in migraine: 2021-2031
    • Forecast
      • Market forecast assumptions: acute migraine
      • Market forecast dashboard: acute migraine
      • Market forecast assumptions: migraine prophylaxis
      • Market forecast dashboard: migraine prophylaxis
    • Etiology and pathophysiology
      • Disease overview
        • Anatomy of the brain
      • Genetic factors
        • Environmental factors: migraine triggers
          • Select precipitating (trigger) factors associated with migraine
        • Key pathways and drug targets
          • Substances involved in neurotransmission in migraine
          • Role of select 5-HT receptor subtypes in migraine
          • Neurogenic inflammation in migraine
          • Neurogenic inflammation in migraine headache
          • Progression of spreading depression and oligemia believed to be associated with migraine aura
          • Other processes involved in migraine
      • Epidemiology
        • Key findings
          • Epidemiology populations
            • Disease definition
            • Sources used for total prevalent cases of migraine
            • 12-month total migraine cases in the major pharmaceutical markets: 2021-2031
            • Disease definition
            • Methods
            • Sources used for total prevalent cases of episodic migraine
            • Total 12-month episodic migraine cases in the major pharmaceutical markets: 2021-2031
            • Disease definition
            • Sources used for total prevalent cases of chronic migraine
            • Total 12-month chronic migraine cases in the major pharmaceutical markets: 2021-2031
            • Disease definition
            • Methods
            • Sources used for frequency of episodic migraine attacks
            • Total 12-month episodic migraine cases according to frequency of attacks in the major pharmaceutical markets: 2021-2031
            • Disease definition
            • Methods
            • Sources used for total episodic migraine events
            • Total 12-month episodic migraine events in the major pharmaceutical markets: 2021-2031
            • Diagnosed prevalent cases of episodic migraine: 2021-2031 (thousands)
            • Diagnosed prevalent cases of chronic migraine: 2021-2031 (thousands)
            • Acute migraine treatment
            • Acutely drug-treated prevalent cases of episodic migraine: 2021-2031 (thousands)
            • Acutely drug-treated prevalent cases of chronic migraine: 2021-2031 (thousands)
            • Migraine prophylaxis
            • Prophylactically drug-treated prevalent cases of episodic migraine: 2021-2031 (thousands)
            • Prophylactically drug-treated prevalent cases of chronic migraine: 2021-2031 (thousands)
        • Current treatment
          • Key findings
            • Treatment goals
              • Key endpoints used in clinical trials for migraine
            • Key current therapies: acute treatment
              • Overview
              • Mechanism of action of key current drug classes used for the acute treatment of migraine
              • Current treatments used for the acute treatment of migraine
              • Market events impacting the use of key current acute therapies in migraine
              • Advantages and disadvantages of sumatriptan
              • Expert insight: sumatriptan
              • Advantages and disadvantages of Treximet
              • Advantages and disadvantages of rizatriptan
              • Advantages and disadvantages of frovatriptan
              • Advantages and disadvantages of zolmitriptan
              • Expert insight: zolmitriptan
              • Advantages and disadvantages of other triptans
              • Advantages and disadvantages of Reyvow
              • Key results from select clinical trials investigating Reyvow for the acute treatment of migraine
              • Ongoing clinical development of Reyvow
              • Expert insight: Reyvow
              • Key results from select clinical trials investigating Ubrelvy for the acute treatment of migraine
              • Ongoing clinical development of Ubrelvy
              • Expert insight: Ubrelvy
              • Advantages and disadvantages of Nurtec ODT / Vydura
              • Key results from select clinical trials investigating Nurtec ODT / Vydura for the acute treatment of migraine
              • Key results from clinical trials investigating Nurtec ODT / Vydura for the prophylactic treatment of migraine
              • Ongoing clinical development of Nurtec ODT / Vydura
              • Expert insight: Nurtec ODT / Vydura
              • Dihydroergotamine mesylate
              • Advantages and disadvantages of dihydroergotamine mesylate
              • Expert insight: DHE
              • Trudhesa
              • Advantages and disadvantages of Trudhesa
              • Key results from clinical trials investigating Trudhesa for the acute treatment of migraine
              • Expert insight: Trudhesa
              • Advantages and disadvantages of Elyxyb
              • Key results from clinical trials investigating Elyxyb for the acute treatment of migraine
              • Expert insight: Elyxyb
              • Advantages and disadvantages of prescription NSAIDs and nonnarcotic analgesics
              • Advantages and disadvantages of narcotic prescription analgesics
            • Key current therapies: prophylactic treatment
              • Overview
              • Mechanism of action of key current drug classes used for the prophylactic treatment of migraine
              • Current treatments used for the prophylactic treatment of migraine
              • Market events impacting the use of key current preventive therapies in migraine
              • Advantages and disadvantages of topiramate
              • Advantages and disadvantages of divalproex
              • Advantages and disadvantages of Botox
              • Advantages and disadvantages of Aimovig
              • Key results from select clinical trials investigating Aimovig for the prophylactic treatment of migraine
              • Ongoing clinical development of Aimovig
              • Expert insight: Aimovig
              • Advantages and disadvantages of Ajovy
              • Key results from select clinical trials investigating Ajovy for the prophylactic treatment of migraine
              • Ongoing clinical development of Ajovy
              • Advantages and disadvantages of Emgality
              • Key results from select clinical trials investigating Emgality for the treatment of migraine
              • Ongoing clinical development of Emgality
              • Expert insight: Emgality
              • Advantages and disadvantages of Vyepti
              • Key results from select clinical trials investigating Vyepti for the treatment of migraine
              • Ongoing clinical development program of Vyepti
              • Qulipta
              • Advantages and disadvantages of Qulipta
              • Key results from clinical trials investigating Qulipta for the prophylactic treatment of migraine
              • Ongoing clinical development of Qulipta
              • Expert insight: Qulipta
              • Advantages and disadvantages of beta blockers
              • Advantages and disadvantages of amitriptyline
              • Advantages and disadvantages of calcium channel blockers
            • Medical practice
              • Overview
              • Factors influencing drug selection in migraine
              • Treatment decision tree for the acute treatment of migraine: United States
              • Treatment decision tree for the prophylactic treatment of migraine: United States
              • Treatment decision tree for the acute treatment of migraine: Europe
              • Treatment decision tree for the prophylactic treatment of migraine: Europe
              • Treatment decision tree for the acute treatment of migraine: Japan
              • Treatment decision tree for the prophylactic treatment of migraine: Japan
          • Unmet need overview
            • Current and future attainment of unmet needs in migraine
            • Top unmet needs in migraine: current and future attainment
            • Expert insight: unmet need in migraine
          • Drug pipeline
            • Pipeline
            • Regulatory Milestones
            • Indication Comparison
          • Emerging therapies
            • Key findings
              • Key emerging therapies
                • Key therapies in development for migraine
                • Estimated launch dates of key emerging therapies for the treatment of migraine
                • AXS-07
                • AXS-07 profile
                • Analysis of clinical development program for AXS-07
                • Expert insight: AXS-07
                • Expectations for launch and sales opportunity of AXS-07 in migraine
                • Qtrypta profile
                • Analysis of clinical development program for Qtrypta
                • Expert insight: Qtrypta
                • Expectations for launch and sales opportunity of Qtrypta (M-207) in migraine
                • STS101
                • STS101 profile
                • Expert insight: STS101
                • Expectations for launch and sales opportunity of STS101 in migraine
                • Zavegepant profile
                • Analysis of clinical development program for zavegepant
                • Expert insight: zavegepant
                • Expectations for launch and sales opportunity of zavegepant in migraine
              • Early-phase pipeline analysis
                • Select compounds in early-phase development for the acute treatment of migraine
                • Select compounds in early-phase development for the prophylactic treatment of migraine
            • Access & reimbursement overview
              • Region-specific reimbursement practices
                • Key market access considerations in migraine: United States
                • General reimbursement environment: United States
                • Key market access considerations in migraine: EU5
                • General reimbursement environment: EU5
                • Key market access considerations in migraine: Japan
                • General reimbursement environment: Japan
            • Appendix
              • Abbreviations
              • Migraine bibliography

          Login to access report

          launch Related Market Assessment Reports